New strategic partnership strengthens Lonza's position as leading supplier to the life science industry
Strategic partnership concluded with Novartis for the joint development and manufacture of its biological pipeline
The collaboration will involve Lonza in the development, scale-up and manufacturing of Novartis biological pipeline. Lonza will provide development services from its R&D center in Slough, UK, using Lonza's GS Gene Expression System(TM), and large scale manufacturing capacity from its operations in the US, Spain and Singapore.
This strategic partnership represents an extension of Lonza's Contract Manufacturing Business model, expanding from a product by product development and manufacturing arrangement towards the joint development of a pipeline of products with its customers.
Novartis has a pipeline of pharmaceutical products in numerous therapeutic areas. The collaboration will fulfill their need for additional resources in technical development. It will also provide Novartis with extra manufacturing capacity, to be utilized in a flexible way.
"We are delighted to enter into this collaboration. For Lonza, it represents a change in approach from a typical CMO deal. It focuses on a real collaborative approach to development and manufacturing asset planning to ensure our customers can bring their pipeline of products to the market in an efficient and timely manner", said Dr. Stephan Kutzer, Head of Lonza Biopharmaceuticals. "We believe this is the beginning of a long partnership that will bring significant benefits to both parties."
Organizations
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.